|
| Mechanism study of Liangdi Decoction in treating menopausal syndrome |
| Hits 217 Download times 58 Received:September 01, 2025 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1673-9043.2026.01.07 |
| Key Words
Liangdi Decoction;menopausal syndrome;inflammaging;network pharmacology;molecular docking |
| Author Name | Affiliation | E-mail | | WANG Ruoxi | Ningxia Medical University, Yinchuan 750000, China
Key Laboratory of Dryness Syndrome in Chinese Medicine, Ministry of Education, Ningxia Medical University, Yinchuan 750000, China | | | YAN Liangyu | Ningxia Medical University, Yinchuan 750000, China
Key Laboratory of Dryness Syndrome in Chinese Medicine, Ministry of Education, Ningxia Medical University, Yinchuan 750000, China | | | DU Xiaoli | Ningxia Medical University, Yinchuan 750000, China
Key Laboratory of Dryness Syndrome in Chinese Medicine, Ministry of Education, Ningxia Medical University, Yinchuan 750000, China
Affiliated Traditional Chinese Medicine Hospital of Ningxia Medical University, Wuzhong 750006, China | dxl710902@163.com |
|
| Abstract
|
| [Objective] To explore the mechanism of Liangdi Decoction（LDD） in treating menopausal syndrome（MPS） based on network pharmacology and in vivo experiments. [Methods] The main active ingredients and target genes of LDD were obtained from databases including HERB（a high-throughput experiment- and reference-guided database of traditional Chinese medicine），PubChem，and SuperPred. Disease targets for MPS were retrieved from GeneCards，OMIM，and DrugBank. The common targets between LDD and MPS were selected and imported into the STRING database to construct a protein-protein interaction（PPI） network. The “drug-active ingredient-target” network was visualized using Cytoscape 3.10.3. Gene Ontology（GO） functional annotation and Kyoto Encyclopedia of Genes and Genomes（KEGG） pathway enrichment analysis were performed using the DAVID database. Molecular docking of core active ingredients with key protein factors in predicted signaling pathways was conducted using AutoDock Tools 1.5.7 and CB-Dock2 to validate potential interactions. In vivo experiments were performed to measure the expression levels of interleukin-6（IL-6），signal transducer and activator of transcription 3（STAT3），phosphorylated STAT3（p-STAT3），Caspase-3，B-cell lymphoma-2（Bcl-2），and hypoxia-inducible factor-1α（HIF-1α），verifying the mechanism of LDD in ameliorating ovarian aging in MPS. [Results] Six core proteins（IL-6，STAT3，HIF-1α，Caspase-3，Bcl-2） and eight key active ingredients（coniferin，sugiol，catechin，isoimperatorin，marmesin，byakangelicol，acacetin，poncimarin） were screened. The molecular docking binding energies were all< -5 kcal/mol. Experiments showed that LDD could down-regulate the protein expression of IL-6，STAT3，HIF-1α，and caspase-3，and up-regulate the expression of Bcl-2. [Conclusion] LDD may delay ovarian aging by inhibiting the HIF-1 signaling pathway，regulating the expression of proteins such as IL-6，STAT3，Caspase-3，and Bcl-2，thereby reducing hypoxia-inducible factor levels and inflammation，and enhancing anti-apoptotic expression. |
|
|
|
|
|
